Dendreon Pays $40M Over Claims It Inflated Provenge Demand
Biotech company Dendreon Corp. has agreed to pay $40 million to end a consolidated putative class action accusing it of misleading investors about demand for its prostate cancer drug Provenge, the...To view the full article, register now.
Already a subscriber? Click here to view full article